Our Team
Lauren Hanson is a former founder turned operator and angel investor who brings a hands-on, in-the-trenches approach to every company she backs. After building and scaling her own healthcare startup from idea to acquisition in 2022 in under two years, she has developed a reputation for getting deep into product, strategy, and execution — not just advising from afar.
As an active angel investor, Lauren has supported early femtech, diagnostic, and digital health startups working to close the systemic gaps that keep women from receiving equitable care.
With Hysteria Ventures, she’s now channeling that same energy into backing founders tackling the hard, overlooked problems — the ones that matter most to patients but rarely get funded.
Lauren believes healthcare should be as dependable, innovative, and worthy as the families who rely on it—and partners closely with founders to build solutions that raise the standard of care, not just the next round.
Callie Chamberlain is a public health leader and social impact strategist focused on building a more equitable healthcare system. With over a decade of experience at UnitedHealth Group and Optum, she was responsible for standing up the company's first Office of Social Responsibility, leading enterprise wide initiatives addressing the social determinants of health, maternal health, and health equity, driving payor innovation and venture partnerships that addressed community needs and closed $3B in revenue gaps.
She has held roles as Entrepreneur in Residence at New Media Ventures and Lead Mentor for Pharrell's Black Ambition Prize. Most recently she was appointed by the NYC Mayor to the Commission for Gender Equity.
At Hysteria Ventures, Callie brings a systems-level lens to investing, helping founders navigate the realities of reimbursement, health equity, and policy while staying true to their mission. She believes better health outcomes start with better incentives and works to ensure the next generation of women’s health companies are built for both impact and access.
What they call niche, we call necessary.
The world doesn’t need more of the same. It needs bold ideas, deep tech, and the people brave enough to take the hard paths.
We invest in what’s often considered too complex, too early, too sensitive, or too slow. Because that’s where change lives.
We show up for:
Tough regulatory pathways
Clinical validation and evidence
Long timelines and slow burn breakthroughs
Taboo, stigmatized, or under-researched areas of health
We don’t just fund. We help build. From clinical support and regulatory guidance to go-to-market strategy and operational lift, we’re in it early and for the long haul.